Book contents
- Frontmatter
- Contents
- List of contributors
- Foreword
- Preface
- 1 The cannabinoid system: from the point of view of a chemist
- 2 How cannabis works in the brain
- 3 Acute and subacute psychomimetic effects of cannabis in humans
- 4 The association between cannabis use and depression: a review of the evidence
- 5 Cannabis and psychosis proneness
- 6 Is there a specific ‘cannabis psychosis’?
- 7 Cannabis as a potential causal factor in schizophrenia
- 8 Cannabis abuse and the course of schizophrenia
- 9 The endogenous cannabinoid system in schizophrenia
- 10 Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia
- 11 Motives that maintain cannabis use among individuals with psychotic disorders
- 12 Addressing cannabis abuse in people with psychosis
- 13 Residual cognitive effects of long-term cannabis use
- Index
- References
12 - Addressing cannabis abuse in people with psychosis
Published online by Cambridge University Press: 07 December 2009
Book contents
- Frontmatter
- Contents
- List of contributors
- Foreword
- Preface
- 1 The cannabinoid system: from the point of view of a chemist
- 2 How cannabis works in the brain
- 3 Acute and subacute psychomimetic effects of cannabis in humans
- 4 The association between cannabis use and depression: a review of the evidence
- 5 Cannabis and psychosis proneness
- 6 Is there a specific ‘cannabis psychosis’?
- 7 Cannabis as a potential causal factor in schizophrenia
- 8 Cannabis abuse and the course of schizophrenia
- 9 The endogenous cannabinoid system in schizophrenia
- 10 Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia
- 11 Motives that maintain cannabis use among individuals with psychotic disorders
- 12 Addressing cannabis abuse in people with psychosis
- 13 Residual cognitive effects of long-term cannabis use
- Index
- References
Summary
As outlined in Chapter 8, cannabis use is common amongst people with schizophrenia and regular use, even at relatively low levels, can have a negative impact on illness course (Hall and Degenhardt, 2000). The effective management of this clinical problem is increasingly the focus of psychiatric practice and research. This chapter reviews a number of important areas that deserve consideration when developing an effective response. Aspects such as screening, assessment and models of service delivery are covered. The chapter concludes by outlining a number of psychosocial treatment interventions available for addressing cannabis use in schizophrenia and related disorders.
It must be acknowledged from the outset that there is a paucity of research evidence in terms of treatment interventions solely for cannabis use amongst people with schizophrenia. Thus, studies that have considered other drugs, and not just cannabis, are included in this review.
Screening
An awareness of any ongoing drug abuse is essential when determining psychiatric diagnosis, deciding on appropriate treatment interventions and planning future care (Zeidonis and Fisher, 1994). If undetected, drugs such as cannabis can confound the interpretation of important signs and symptoms of psychosis, possibly lead to overmanagement with psychotropic medications, as well as rendering other psychosocial treatments less effective for people with schizophrenia (Drake et al., 1993b).
- Type
- Chapter
- Information
- Marijuana and MadnessPsychiatry and Neurobiology, pp. 186 - 197Publisher: Cambridge University PressPrint publication year: 2004
References
, , , et al. (1989). Missed diagnosis of substance abuse in psychiatric patients. Hosp. Commun. Psychiatry, 40, 297–299Google ScholarPubMed
, , and (1997). The impact of substance use screening on a public psychiatric inpatient population. Psychiatric Serv., 48, 1311–1316Google ScholarPubMed
(2001). Pharmacology and effects of cannabis: a brief review. Br. J. Psychiatry, 178, 101–106CrossRefGoogle ScholarPubMed
, and (2001). Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am. J. Psychiatry, 158, 1706–1713CrossRefGoogle ScholarPubMed
and (1999). Treating substance abuse among patients with schizophrenia. Psychiatric Serv., 50, 75–80CrossRefGoogle ScholarPubMed
and (1998). Substance abuse treatment for people with schizophrenia. Addict. Behav., 23, 749–766CrossRefGoogle ScholarPubMed
and (1998). Severe mental illness and addictions: assessment considerations. Addict. Behav., 23, 735–748CrossRefGoogle ScholarPubMed
, , et al. (2001) Readiness to change substance misuse among psychiatric outpatients: reliability and validity of self-report measures. J. Studies Alcohol, 62, 79–88CrossRefGoogle Scholar
, , et al. (2002). Substance use in schizophrenia: why do people use, and what can be done about it?Schizophr. Res., 53, 223Google Scholar
, , and (1995). Drinking to regulate positive and negative emotions: a motivational model of alcohol use. J. Personal. Soc. Psycho., 69, 990–1005CrossRefGoogle ScholarPubMed
Department of Health (2002). Mental Health Policy Implementation Guide: Dual Diagnosis Good Practice Guide. London: Department of Health
, , , and (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry, 148, 224Google ScholarPubMed
and (2000). Psychosocial approaches to dual diagnosis. Schizophr. Bull., 26, 105–118CrossRefGoogle ScholarPubMed
and (1989). Substance abuse among the chronic mentally ill. Hosp. Commun. Psychiatry, 40, 1041–1046Google ScholarPubMed
, , , and (1993a). Treatment of substance abuse in severely mentally ill patients. J. Nerv. Ment. Dis. 24, 589–608Google Scholar
, and (1993b). Detection of substance use disorders in severely mentally ill patients. Commun. Ment. Health J., 29, 175–192CrossRefGoogle Scholar
, , et al. (2001). Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Serv., 52, 469–476CrossRefGoogle ScholarPubMed
and (2000). Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust. NZ J. Psychiatry, 34, 26–34CrossRefGoogle ScholarPubMed
James, W., Koh, G., Spencer, C. et al. (2002). Managing Mental Health and Drug Use. Perth, Western Australia: Uniprint
, et al. (2004). A group intervention that assists patients with dual diagnosis reduce their drug and alcohol use: a randomised controlled trial. Psychol. Med. (in press)CrossRefGoogle Scholar
(1995). An intervention for substance abuse in schizophrenia. Behav. Change, 12, 20–30CrossRefGoogle Scholar
Kavanagh, D. (2000). Treatment of Comorbidity. National Comorbidity Project–National Workshop Agenda Papers. Canberra. Available from Department of Psychiatry, University of Queensland
, et al. (1998). Substance Treatment Options in Psychosis (STOP): a new intervention for dual diagnosis. J. Men. Health, 7, 135–143Google Scholar
Ley, A., McLaren, S. and Siegfried, N. (2001). Treatment programmes for people with both severe mental illness and substance misuse (Cochrane Review). Cochrane Library, Issue 1
, and (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry, 51, 273–279CrossRefGoogle ScholarPubMed
Marlatt, G. and Gordon, J. (1985). Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviours. New York: Guildford Press
, , et al. (1997). The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 93, 1857–1868CrossRefGoogle Scholar
, and (1974). The CAGE questionnaire: validation of a new alcoholism instrument. Am. J. Psychiatry, 131, 1121–1123Google Scholar
, , et al. (1992). The fifth edition of the Addiction Severity Index. J. Substance Abuse Treatment, 9, 199–213CrossRefGoogle ScholarPubMed
(1996). Motivational interviewing: research, practice and puzzles. Addict. Behav., 61, 835–842CrossRefGoogle Scholar
Miller, W. and Rollnick, S. (1991). Motivational Interviewing: Preparing People to Change Addictive Behaviour. New York: Guildford Press
and (1996). Assessing Drinker's motivation for change: the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychol. Addict. Behav., 10, 81–89CrossRefGoogle Scholar
, and (1994). Problems, in the recognition and treatment of patients with dual diagnosis. J. Substance Abuse Treatment, 11, 267–271CrossRefGoogle Scholar
and (1989). Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp. Commun. Psychiatry, 40, 1025–1030Google ScholarPubMed
Prochasca, J. and DiClemente, C. (1986). Toward a comprehensive model of change. In Treating Addictive Behaviours: Process of Change. ed. W. R. Miller and N. Heather. New York: PlenumCrossRef
, and (1999). Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatric Serv., 50, 1427–1433CrossRefGoogle ScholarPubMed
, , et al. (1999a). Cannabis use, symptom profile and quality of life in clients enrolled in the Schizophrenia Care and Assessment Program (SCAP). International Congress on Schizophrenia Research, Santa Fe, April 1999. Schizophr. Bull. (suppl.)Google Scholar
Rolfe, T. J. Williams, S., Fitzgerald, P. B. and Kulkarni, J.(1999b). Cannabis use in schizophrenia. R Aust NZ J Psychiatry, (supp.)
, , et al (1998). Dartmouth assessment of lifestyle instrument (DALI): a substance use disorder screen for people with severe mental illness. Am. J. Psychiatry, 155, 232–238Google ScholarPubMed
(1998). A review of comorbidity: major mental illness and problematic substance use. Aust. NZ J. Psychiatry, 32, 707–717CrossRefGoogle ScholarPubMed
, and (2002). An examination of the validity of a motivational model for understanding substance use among individuals with psychotic disorders. Schizophr. Bull., 28, 233–247CrossRefGoogle Scholar
, and (1994). Treating adult marijuana dependence: a test of the relapse prevention model. J. Consult. Clin. Psychol., 62, 92–99CrossRefGoogle ScholarPubMed
, and (1989). Substance use in young adults with schizophrenic disorders. Schizophr. Bull., 15, 465–476CrossRefGoogle ScholarPubMed
, , et al. (1998). Validity of substance use self-reports in dually diagnosed outpatients. Am. J. Psychiatry, 155, 127–128CrossRefGoogle ScholarPubMed
and (1994). Assessment and treatment of comorbid substance abuse in individuals with schizophrenia. Psychiatric Ann., 24, 477–483CrossRefGoogle Scholar
- 2
- Cited by